Gavreto Archives -

Eli Lilly’s tissue-agnostic cancer drug Retevmo has just had its eligible patient population increased in the US. The

Lilly bags label extension for RET drug Retevmo in US

https://pharmaphorum.com/news/lilly-bags-label-extension-for-ret-drug-retevmo-in-us/

Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some

Blueprint cashes in on the past to build its future

https://pharmaphorum.com/news/blueprint-cashes-in-on-the-past-to-build-its-future/

Eli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced

After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancer

https://pharmaphorum.com/news/after-scotland-says-no-nice-backs-lillys-retsevmo-for-lung-cancer/

Roche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers,

Roche, Blueprint’s RET cancer drug Gavreto cleared in EU

https://pharmaphorum.com/news/roche-blueprints-ret-cancer-drug-gavreto-cleared-in-eu/

The FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

https://pharmaphorum.com/news/roche-blueprint-raise-pressure-on-lilly-with-new-gavreto-approval/

Gavreto